Category: Biotechnology

Direct Biologics, LLC Announces One Year Follow Up of Pilot Safety Study of ExoFlo for Treatment of Osteoarthritis in Combat-Related Injuries
Press Release Nov 11, 2021
Direct Biologics, LLC Announces One Year Follow Up of Pilot Safety Study of ExoFlo for Treatment of Osteoarthritis in Combat-Related Injuries

Thirty-three Navy SEAL veterans were treated with a bone marrow mesenchymal stem cell (MSC) derived extracellular vesicle isolate product (EVIP) for Osteoarthritis (OA) of the knee, shoulder, elbow, hip, ankle, or wrist.